Company intelligence / Profile preview
Prazer Therapeutics
Seoul, South Koreaprazertx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Prazer Therapeutics is developing targeted protein degradation therapies with a focus on previously undruggable targets. Their proprietary SPiDEM platform can target membrane-bound and aggregated proteins through both proteasome and lysosome pathways. They have preclinical candidates for Alzheimer's disease, various cancers, and autoimmune conditions.
- Therapeutic areas
- OncologyImmunologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Kyung Hee UniversityYuhan CorporationDaewon Pharmaceutical
Beyond the preview
Go deeper on Prazer Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prazer Therapeutics.